Study to Evaluate DNL201 in Subjects With Parkinson's Disease

Inclusion Criteria:

- Body mass index (BMI) between 18 and 35.0 kg/m2, inclusive

- Clinical diagnosis of Parkinson's disease meeting UK Brain Bank criteria and H&Y Stage
I, II, or III.

- sPD subgroup without a LRRK2 mutation; PD LRRK2 subgroup with LRRK2 mutation

- Screening dopamine transporter (DAT) SPECT scan with a DAT deficit consistent with
Parkinson's disease

- Able to hold Parkinson's disease medications 8 hours (overnight) prior to specific
study assessments

Exclusion Criteria:

- Any history of clinically significant asthma, chronic obstructive pulmonary disease,
or emphysema within 5 years of screening, or other clinically significant pulmonary
disease within 6 months of screening

- Abnormal Vitals including Respiratory Rate, Body Temperature, and Blood Pressure

- Pulmonary Function Tests (PFTs) (FVC <60% predicted, FEV1 <50% predicted, FEV1:FVC
ratio <0.6, DLCO <70% predicted)

- Clinically significant neurologic disorder other than Parkinson's disease, including
history of stroke, cognitive impairment, seizure within 5 years of screening, or head
trauma with loss of consciousness within 6 months of screening

- Montreal Cognitive Assessment (MoCA) score of <24 at screening